CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Paul Haber

OPENALEX: A5071884095↗ORCID: 0000-0001-8915-8872↗

Affiliations

Organizations

Centre for Addiction and Mental Healthauthorship · CA National Health and Medical Research Councilauthorship · AU Royal Prince Alfred Hospitalauthorship · AU Sydney Local Health Districtauthorship · AU The University of Sydneyauthorship · AU UNSW Sydneyauthorship · AU

Public evidence

5 connected articles

A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.2024 · Europe PMC Different Tokes for Different Folks: Use of Cannabis Products Among a Longitudinal Cohort of People with Heroin Dependence.2023 · PubMed Central Open Access Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.2019 · Europe PMC Detection of Δ<sup>9</sup> THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point-of-collection testing devices.2019 · Europe PMC Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).2018 · Europe PMC

Matched by exact identifiers only. Profile data: ORCID. Last retrieved 23/08/2026.

Paul Haber - Medical Cannabis Research Engine